Medtronic Resolute Drug-Eluting Stent (DES) Platform Receives FDA’s Approval for Expanded Indication for Chronic Total Occlusion (CTO)

Medtronic Resolute Drug-Eluting Stent (DES) Platform Receives FDA’s Approval for Expanded Indication for Chronic Total Occlusion (CTO)

Shots:

  • The expanded indication approval is based on PERSPECTIVE Study assessing 183 patients with older-generation Resolute Integrity DES
  • The study resulted in low rates of repeat revascularization 1.1%, cardiac death 2.2%, minimal stent thrombosis 0.06% and safe results
  • Resolute Drug-Eluting Stent (DES) platform includes Resolute Onyx and Resolute Integrity DES targeted for the treatment of patients with coronary artery disease who have de novo chronic total occlusion (CTO)

Click here to read full press release/ article | Ref: Medtronic | Image: Business Daily